Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand

Lv,Yuandong; Wang,Guihua; Xu,Weihong; Tao,Pinghua; Lv,Xiaoling; Wang,Yazhen

doi:10.3892/etm.2014.2071

Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand

Authors:
- Yuandong Lv
- Guihua Wang
- Weihong Xu
- Pinghua Tao
- Xiaoling Lv
- Yazhen Wang
View Affiliations

Affiliations: Zhejiang Provincial Key Laboratory of Geriatrics, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China
Published online on: November 14, 2014 https://doi.org/10.3892/etm.2014.2071
Pages: 143-146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tartrate-resistant acid phosphatase 5b (TRACP 5b) has been used as a biomarker of bone resorption and cancer metastasis. TRACP 5b has also been suggested to be a reliable marker of osteoclast number. In this study, the correlation of TRACP 5b level and osteoclast-like cell number was investigated in RAW 264.7 cells treated with receptor-activated nuclear factor κB ligand (RANKL). RAW 264.7 cells were cultured with α-MEM containing RANKL (40 ng/ml) for 3, 5 and 7 days. Osteoclast formation and TRACP 5b levels were determined by TRACP staining, scanning electron microscopy and enzyme-linked immunosorbent assay. The RAW 264.7 cells that were not exposed to RANKL did not secrete TRACP 5b. RANKL induced the RAW 264.7 cells to differentiate into osteoclasts and to secrete TRACP 5b. The TRACP 5b level in the RAW 264.7 cells treated with RANKL was significantly correlated with the number and volume of osteoclasts (r=0.95 and r=0.92, respectively; P<0.0001). TRACP 5b is a good marker of RANKL‑induced osteoclast formation in RAW 264.7 cells. TRACP 5b analysis may be used as an alternative to osteoclast counting in vitro.

View Figures

View References

1	Väänänen HK, Zhao H, Mulari M and Halleen JM: The cell biology of osteoclast function. J Cell Sci. 113:377–381. 2000.PubMed/NCBI
2	Blair HC and Athanasou NA: Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol. 19:189–199. 2004.PubMed/NCBI
3	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
4	Cuetara BV, Crotti TN, O’Donoghue AJ and McHugh KP: Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim. 42:182–188. 2006. View Article : Google Scholar : PubMed/NCBI
5	MacDonald BR, Takahashi N, et al: Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology. 120:2326–2333. 1987. View Article : Google Scholar : PubMed/NCBI
6	Udagawa N, Takahashi N, Akatsu T, et al: Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. 87:7260–7264. 1990. View Article : Google Scholar : PubMed/NCBI
7	Higuchi S, Tabata N, Tajima M, et al: Induction of human osteoclast-like cells by treatment of blood monocytes with anti-fusion regulatory protein-1/CD98 monoclonal antibodies. J Bone Miner Res. 13:44–49. 1998. View Article : Google Scholar : PubMed/NCBI
8	Halleen JM, Alatalo SL, Suominen H, et al: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 15:1337–1345. 2000. View Article : Google Scholar : PubMed/NCBI
9	Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM and Väänänen HK: Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 52:499–509. 2006.PubMed/NCBI
10	Alatalo SL, Halleen JM, et al: Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem. 46:1751–1754. 2000.PubMed/NCBI
11	Rissanen JB, Suominen MI, Peng ZQ and Halleen JM: Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. 82:108–115. 2008. View Article : Google Scholar
12	Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 96:3540–3545. 1999. View Article : Google Scholar : PubMed/NCBI
13	Thompson CD, Frazier-Jessen MR, Rawat R, Nordan RP and Brown RT: Evaluation of methods for transient transfection of a murine macrophage cell line, RAW 264.7. Biotechniques. 27:824–832. 1999.PubMed/NCBI
14	Yu X, Huang Y, Collin-Osdoby P and Osdoby P: CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 19:2065–2077. 2004. View Article : Google Scholar : PubMed/NCBI
15	Battaglino R, Fu J, Späte U, et al: Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 19:1420–1431. 2004. View Article : Google Scholar : PubMed/NCBI
16	Mose S, Menzel C, Kurth AA, et al: Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases. Anticancer Res. 25:4639–4645. 2005.PubMed/NCBI
17	Qin YJ, Zhang ZL, Zhang H, et al: Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women. Acta Pharmacol Sin. 29:1493–1498. 2008. View Article : Google Scholar : PubMed/NCBI
18	Nenonen A, Cheng S, Ivaska KK, et al: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 20:1804–1812. 2005. View Article : Google Scholar : PubMed/NCBI
19	Alatalo SL, Ivaska KK, Waguespack SG, et al: Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 50:883–890. 2004. View Article : Google Scholar : PubMed/NCBI
20	Alatalo SL, Ivaska KK, Peng Z, et al: Serum tartrate-resistant acid phosphatase 5b and osteocalcin in naturally occurring osteopetrotic rats. J Bone Miner Res. 18(Suppl): S952003. View Article : Google Scholar
21	Xiao XH, Liao EY, Zhou HD, et al: Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro. J Endocrinol Invest. 28:253–260. 2005. View Article : Google Scholar : PubMed/NCBI
22	Abe K, Yoshimura Y, Deyama Y, et al: Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Int J Mol Med. 29:1007–1015. 2012.PubMed/NCBI
23	Teramachi J, Morimoto H, Baba R, et al: Double stranded RNA-dependent protein kinase is involved in osteoclast differentiation of RAW264.7 cells in vitro. Exp Cell Res. 316:3254–3262. 2010. View Article : Google Scholar : PubMed/NCBI
24	GuezGuez A, Prod’homme V, Mouska X, et al: 3BP2 Adapter protein is required for receptor activator of NF kappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem. 285:20952–20963. 2010. View Article : Google Scholar : PubMed/NCBI
25	Nishida T, Emura K, Kubota S, Lyons KM and Takigawa M: CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 26:351–363. 2011. View Article : Google Scholar